Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Galectin Therapeutics Inc - SIC # 2834 - PHARMACEUTICAL PREPARATIONS
Ticker
Exchange
SIC #
Website
Latest Ticker
GALT
Nasdaq
2834
https://galectintherapeutics.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Galectin Therapeutics Inc
Galectin Therapeutics Expands Clinical Team with the Appointment of Khurram Jamil, M.D. as Vice President, Clinical Development
- Mar 12th, 2024 12:00 pm
Retail investors account for 55% of Galectin Therapeutics Inc.'s (NASDAQ:GALT) ownership, while insiders account for 21%
- Feb 21st, 2024 11:53 am
Galectin Therapeutics Inc (GALT) Reports Increased Net Loss in Q3 2023
- Nov 13th, 2023 4:11 pm
UPDATE – Galectin Therapeutics Reports Financial Results for the Quarter Ended September 30, 2023 and Provides Business Update
- Nov 13th, 2023 1:45 pm
Galectin Therapeutics Reports Financial Results for the Quarter Ended September 30, 2023 and Provides Business Update
- Nov 13th, 2023 1:00 pm
Galectin Therapeutics to Share Five Scientific Presentations at The Liver Meeting™ 2023, Hosted by the AASLD
- Nov 3rd, 2023 12:00 pm
Galectin Therapeutics to Participate in the H.C. Wainwright 7th Annual NASH Investor Conference on October 24, 2023
- Oct 23rd, 2023 12:00 pm
Galectin Therapeutics Announces Nomination of Dr. Benjamin S. Carson, Sr. to Board of Directors
- Oct 12th, 2023 12:00 pm
Galectin Therapeutics Reports the Positive Outcome of the Fourth Data and Safety Monitoring Board Meeting for NAVIGATE, its Seamless, Adaptive Phase 2b/3 Study of Belapectin in Patients with Portal Hypertension Caused by Non-Alcoholic SteatoHepatitis Liver Cirrhosis
- Oct 3rd, 2023 12:00 pm
Galectin Therapeutics to Present Update on its Belapectin Liver Cirrhosis Program at the 20th Edition of Discovery on Target meeting, in Boston, September 25-28, 2023
- Sep 26th, 2023 12:00 pm
Galectin Therapeutics Inc. (NASDAQ:GALT) surges 16%; individual investors who own 59% shares profited along with insiders
- Sep 14th, 2023 10:26 am
Galectin Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference on September 13, 2023
- Sep 13th, 2023 9:22 pm
Galectin Therapeutics Inc. (GALT)'s Technical Outlook is Bright After Key Golden Cross
- Sep 11th, 2023 1:55 pm
Galectin Therapeutics to Present Data on Liver Cirrhosis at the 9th Edition of the Paris NASH meeting, at Institut Pasteur, September 7th & 8th 2023
- Sep 7th, 2023 4:00 pm
What Makes Galectin Therapeutics Inc. (GALT) a New Buy Stock
- Aug 17th, 2023 4:00 pm
Galectin Therapeutics Reports Financial Results for the Quarter Ended June 30, 2023 and Provides Business Update
- Aug 14th, 2023 12:00 pm
7 Short-Interest Stocks to Target for Explosive Gains
- May 18th, 2023 8:37 pm
Galectin Therapeutics Reports Financial Results for the Quarter Ended March 31, 2023 and Provides Business Update
- May 15th, 2023 12:00 pm
Galectin Therapeutics to Participate in the H.C. Wainwright BioConnect Investment Conference May 2, 2023
- Apr 27th, 2023 12:00 pm
Galectin Therapeutics’ Statement Following the Recent 2023 Emerging Topic Conference on NASH Cirrhosis, Sponsored by the American Association for the Study of Liver Diseases
- Apr 18th, 2023 12:00 pm
Scroll